Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
Page 25
16
th
EuroSciCon Conference on Immunology
March 11-12, 2019 | Amsterdam, Netherlands
Immunology 2019
I
n vivo efficacy evaluation has always been a rate-limiting step during
therapeutic antibody discovery due to species specificity. Using gene-
editing technology, we have generated and functionally validated a series
of single and double humanized mouse models for the I/O field such as
B-hPD-1/hPD-L1, B-CTLA-4, B-hOX-40, B-hCD47/h-SIRPa and B-hCD3e.
Thesemodels are very useful not only for single agent treatment, but also for
combination therapy and bispecific antibody development.
Novel I-O Drug Discoveries Empowered
by Humanized Animal Models
Yi Yang
Biocytogen, China
Biography
Dr. Yi (Benny) Yang received his Ph.D. degree in
immunology from University of Connecticut and
completed his postdoctoral training in New York
University at Dr. Dan R. Littman’s group. Dr. Yang
was a tenure-track Assistant Professor at Medical
University of South Carolina from 2014 to 2016 and
joined Biocytogen in 2016. He studied the newly
discovered immune regulation of Th17 cells and
intestinal microbial immunity, and published a series
of paper on Nature, Science and Cell.
info@biocytogen.comYi Yang, J Clin Immunol Allergy 2019, Volume:5
DOI: 10.21767/2471-304X-C1-007